Relapsing Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluating the efficacy of Ofatumumab on microglial activity in patients with Relapsing Multiple Sclerosis has completed and…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset [Phase 4]
The update summarizes a Phase 4 study evaluating the effects of ocrelizumab on cerebrospinal fluid biomarkers at the onset of multiple scler…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
A clinical trial update describes ongoing recruitment to assess the efficacy and safety of ofatumumab in Relapsing multiple sclerosis and it…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
The MASTER-2 trial in relapsing multiple sclerosis, evaluating suboptimally controlled participants previously on oral or infusion disease-m…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
A clinical trial comparing early versus late use of Kesimpta (ofatumumab) in Austrian patients with relapsing multiple sclerosis, with the s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
A cross-sectional real-world study assessing the effectiveness and safety of Kesimpta (ofatumumab) in patients with relapsing multiple scler…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
An observational study evaluating Kesimpta (ofatumumab) in Greek patients with relapsing multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) [Phase 2]
MoonStone is a Phase 2 study of obexelimab for relapsing multiple sclerosis; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab [Phase 3]
Phase 3 open-label trial evaluating the effectiveness and patient-reported outcomes of switching relapsing MS patients from dimethyl fumarat…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China [Phase 4]
A Phase 4 study evaluating the efficacy and safety of ofatumumab in Relapsing Multiple Sclerosis patients in China has completed and results…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis [Phase 2]
The Phase 2 long-term safety and efficacy trial of tolebrutinib in relapsing multiple sclerosis has completed and results have been posted.
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod [Phase 4]
A Phase 4 prospective study is evaluating sequencing of anti-CD20 therapies before starting Ozanimod in Relapsing Multiple Sclerosis, curren…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients [Phase 4]
Phase 4 study evaluating the efficacy and safety of fingolimod 0.5 mg in Chinese patients with relapsing multiple sclerosis; results have be…
-
CLINICAL_TRIALS other · 2025-08-24Clinical Trial Update: A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS) [Phase 4]
Phase IV clinical trial update for dimethyl fumarate enteric-coated capsules in relapsing multiple sclerosis. The study status is not yet re…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis [Phase 3]
A Phase 3, non-inferiority trial comparing subcutaneous versus intravenous ocrelizumab in relapsing and primary progressive multiple scleros…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
A completed real-world study evaluating Relapsing Multiple Sclerosis patients treated with ofatumumab or ocrelizumab in the Gulf region.
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) [Phase 3]
Phase 3 GEMINI 2 trial evaluating tolebrutinib (SAR442168) for relapsing forms of multiple sclerosis has completed, and results have been po…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) [Phase 3]
Phase 3 GEMINI 1 trial of the BTK inhibitor tolebrutinib (SAR442168) for relapsing multiple sclerosis has completed enrollment, with results…
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Study of Evobrutinib in Participants With RMS (evolutionRMS 1) [Phase 3]
A Phase 3 study of evobrutinib in relapsing multiple sclerosis was terminated, with results posted on ClinicalTrials.gov.
-
CLINICAL_TRIALS research · 2025-04-16Clinical Trial Update: A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial evaluating the effectiveness and safety of Ozanimod in Chinese adults with relapsing multiple sclerosis; the study …
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis [Phase 3]
A long-term extension of a Phase 3 trial evaluating ponesimod 20 mg in relapsing multiple sclerosis has completed and results have been post…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Study of Evobrutinib in Participants With RMS (evolutionRMS 2) [Phase 3]
A Phase 3 study of evobrutinib in relapsing multiple sclerosis was terminated with results posted.
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
An observational study in Portugal is evaluating ofatumumab for relapsing multiple sclerosis and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) [Phase 3]
Phase 3 NOR-MS trial evaluating oral cladribine in combination with rituximab for relapsing multiple sclerosis has completed. The study inve…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab [Phase 4]
Phase 4 clinical trial update reporting results on the immune response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis …